Effects of tiludronate: A Synthesis of Findings from 24 Studies

  1. Home
  2. Effects of tiludronate
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of tiludronate: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of tiludronate: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major findings

Tiludronate has been shown to be effective in treating Paget's disease of bone, a condition characterized by increased bone turnover and abnormal bone structure. 21 A study comparing the effects of tiludronate and risedronate on Paget's disease activity found that both drugs had similar effects on bone markers and bone scintigraphy. 7 Tiludronate is also being investigated for the treatment of osteoporosis. 8 It is expected to become a major indication for this drug.

Studies have examined the mechanism by which bisphosphonates, including tiludronate, interact with bone mineral. 11 These studies have shown that bisphosphonates bind to bone mineral in a deprotonated state, and that the strength of this binding can vary depending on the bisphosphonate's side chain structure. For instance, tiludronate has a weaker affinity for bone mineral compared to alendronate and exhibits more dynamic side chain structures when bound to the mineral.

In a study evaluating the use of tiludronate in horses with navicular syndrome, an inflammatory condition affecting the horse's hoof, tiludronate treatment was not found to be more effective than traditional treatments such as shoeing and anti-inflammatory injections. 3 However, horses receiving higher doses of tiludronate showed a reduction in lameness compared to those receiving lower doses or placebo.

Benefits and risks

Benefits summary

Tiludronate has shown promise in treating Paget's disease of bone by reducing bone turnover and improving bone structure. 21 It is also being investigated as a potential treatment for osteoporosis. 8 This drug has shown similar effectiveness to risedronate in treating Paget's disease. 7

Risks summary

While tiludronate offers potential benefits in bone health, there are potential risks associated with its use. Some studies suggest that tiludronate might inhibit bone formation, which could be detrimental in certain conditions. 5 Additionally, concerns have been raised regarding the possibility of tiludronate inhibiting bone mineralization, potentially leading to osteomalacia, a condition characterized by soft bones. 24 , 4 Further research is needed to fully understand the long-term effects of tiludronate on bone health.

Comparison across studies

Commonalities across studies

Multiple studies have consistently shown that tiludronate effectively inhibits bone resorption, a key process in bone metabolism. 7 , 21 , 8 , 14 This property makes it a promising candidate for treating conditions like Paget's disease and osteoporosis, which involve excessive bone breakdown. 8 , 21 Additionally, some research suggests that tiludronate may stimulate bone formation, potentially contributing to improved bone health. 18

Differences across studies

The effects of tiludronate on bone mineral have been observed to vary across studies. 11 shows that tiludronate binds to bone mineral in a deprotonated state, with weaker affinity compared to alendronate, suggesting a less impactful effect on bone mineral. In contrast, 3 found that while tiludronate did not provide additional benefit for navicular syndrome, higher doses showed a reduction in lameness, suggesting a potential dose-dependent impact. Additionally, some research suggests a potential for tiludronate to inhibit bone formation, which contrasts with its potential bone-building properties. 5 , 18 Furthermore, concerns have been raised about tiludronate's potential to inhibit bone mineralization, which could lead to osteomalacia. 24 , 4

Consistency and contradictions in findings

While there is consistent evidence that tiludronate effectively inhibits bone resorption, 7 , 21 , 8 , 14 its impact on bone formation and mineralization remains a subject of debate. Some research suggests a potential for tiludronate to stimulate bone formation. 18 However, other studies point to potential inhibition of bone formation. 5 Similarly, concerns exist about tiludronate's potential to interfere with bone mineralization, which could lead to weakened bones. 24 , 4 Further research is necessary to clarify these discrepancies and understand the full spectrum of tiludronate's effects on bone.

Implications for everyday life

Tiludronate's therapeutic potential for conditions like Paget's disease and osteoporosis is evident. 8 , 21 However, its use should be carefully considered, weighing potential benefits against potential risks. 8 , 21 , 24 , 4 , 14 It's crucial to consult a healthcare professional who can assess individual needs and risks before starting any treatment with tiludronate.

Limitations of current research

More research is needed to gain a comprehensive understanding of the effects of tiludronate on bone health. 8 , 21 , 24 , 4 , 14 Long-term studies are crucial to assess the long-term impact of tiludronate on bone mineralization and formation. 24 , 4 Additionally, more research is required to understand how tiludronate affects different bone diseases, age groups, and genders. 8 , 21 , 24 , 4 , 14

Future research directions

Further research should aim to comprehensively understand the effects of tiludronate on bone. 11 , 3 , 24 , 4 , 18 , 5 Long-term studies are crucial to assess the long-term impact of tiludronate on bone mineralization and formation. 24 , 4 Research should also delve deeper into the effects of tiludronate on bone formation, 18 , 5 and investigate its impact on different bone diseases, age groups, and genders. 8 , 21 , 24 , 4 , 14 These research endeavors will contribute to a more comprehensive understanding of tiludronate's effects on bone and inform the development of safer and more effective bone-related medications.

Conclusion

Tiludronate holds potential as a treatment for bone disorders like Paget's disease and osteoporosis. 8 , 21 While it effectively inhibits bone resorption, 7 , 21 , 8 , 14 its impact on bone formation and mineralization requires further investigation. 18 , 5 , 24 , 4 If you are considering tiludronate treatment, it's crucial to consult a healthcare professional who can assess your individual needs and risks before starting any treatment. 8 , 21 , 24 , 4 , 14 Ongoing research will be vital in clarifying the full effects of tiludronate on bone and guiding the development of safer and more effective therapies for bone-related conditions. 11 , 3 , 24 , 4 , 18 , 5

Literature analysis of 24 papers
Positive Content
22
Neutral Content
0
Negative Content
2
Article Type
2
0
1
5
24
1.

Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model.

Author: MoreauMaxim, RiallandPascale, PelletierJean-Pierre, Martel-PelletierJohanne, LajeunesseDaniel, BoileauChristielle, CaronJudith, FrankDiane, LussierBertrand, del CastilloJerome R E, BeauchampGuy, GauvinDominique, BertaimThierry, ThibaudDominique, TroncyEric

Reduced gait disability
Reduced joint symptoms

This randomized controlled study evaluated the effects of tiludronate (TLN) on structural, biochemical, and molecular changes in an experimental dog model of osteoarthritis (OA). TLN treatment demonstrated a positive effect on gait disability and joint symptoms, likely related to improved OA structural changes and reduced synthesis of catabolic and inflammatory mediators.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Bisphosphonates for osteoporosis.

Author:

Osteoporosis prevention
Osteoporosis treatment

Osteoporosis affects many people and bisphosphonates are a common treatment option. This abstract compares three licensed bisphosphonates for osteoporosis treatment in the UK: alendronate, etidronate, and risedronate.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Quantitative assessment of intravenous regional limb perfusion of tiludronate as an adjunctive treatment for lameness caused by navicular syndrome in horses.

Author: SchoonoverMike J, WhitfieldChase T, YoungJenna M, SippelKate M, PaytonMark E

Improved lameness

Two intravenous regional limb perfusion (IVRLP) protocols involving tiludronate were tested in 15 horses with bilateral forelimb navicular syndrome. Neither protocol showed any further improvement in lameness over therapeutic shoeing and anti-inflammatory injection of the distal interphalangeal joint (DIPJ). However, horses treated with a higher dose of tiludronate were objectively less lame than those treated with a lower dose or placebo at 120 days.

Clinical Trial, VeterinaryClinical trials involving animals. They are conducted to evaluate the safety and efficacy of new drugs and treatments and contribute to the advancement of veterinary medicine.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone.

Author: DevogelaerJ P, MalghemJ, StasseP, Nagant de DeuxchaisnesC

Paget's disease treatment
Bone mineralization defects

Tiludronate was more effective than etidronate in treating Paget's disease of bone. All positive bone balances were observed in the tiludronate group, except for three questionable densifications in the etidronate group.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents.

Author: WimalawansaS J

BMD increase
Osteoporosis prevention

Combination therapies, such as HRT with bisphosphonates, calcitonin, or androgens, may offer additional benefits for osteoporosis compared to single-drug therapy, particularly in patients with high bone turnover or severe osteoporosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.

Author: PerisP, AlvarezL, VidalS, MartínezM A, MonegalA, GuañabensN

Reduced bone turnover

Tiludronate and risedronate given at the currently recommended dosages induce similar responses in Paget's disease activity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Tiludronate: development as an osteoporosis therapy.

Author: ChesnutC H

Osteoporosis treatment
Vertebral fractures

Tiludronate is being investigated for the treatment of osteoporosis. Clinical trials are underway to assess its efficacy in preventing vertebral fractures and increasing bone mineral density.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1.

Author: DelgusteC, AmoryH, GuyonnetJ, ThibaudD, GarneroP, DetilleuxJ, LepageO M, DoucetM

Bone health

Tiludronate, a medication used to treat bone disease in horses, is equally effective whether given intravenously as a single daily dose or as a continuous infusion. Both methods of administration result in similar levels of the drug in the bloodstream and similar effects on bone metabolism.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.

Author: IronsideMatthew S, DuerMelinda J, ReidDavid G, ByardStephen

Pharmacokinetics
Targeting efficacy
Therapeutic and diagnostic applications

Bisphosphonates are drugs that are used to treat osteoporosis and other bone disorders. This study investigated the ways in which bisphosphonates bind to bone mineral. The study found that bisphosphonates bind to bone mineral in a way that is dependent on their molecular structure and flexibility.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

[Factors that determine intensity of response to treatment with tiludronate in Paget's disease].

Author: Morales PigaA, Abraira SantosV, Rey ReyJ S, de Abajo IglesiasF

Bone pain relief
SAP reduction
Mild side effects

Tiludronate effectively suppresses clinical and biochemical activity in Paget's bone disease. Minimum plasma concentration of tiludronate was the best predictor of biochemical response.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : Spanish

14.

Bisphosphonates in the treatment of osteoporosis.

Author: BellN H, JohnsonR H

Bone resorption inhibition
Fracture prevention
Increased bone density
Gastrointestinal disturbances
Osteomalacia

Bisphosphonates inhibit bone resorption, with varying potencies. They are generally well tolerated, but higher doses can cause gastrointestinal disturbances.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia.

Author: DumonJ C, MagritteA, BodyJ J

Treats hypercalcemia
Kidney toxicity
Nausea
Vomiting

Tiludronate, a bisphosphonate, was evaluated for the treatment of hypercalcemia in 19 cancer patients. While effective in lowering serum calcium levels, high intravenous doses were potentially nephrotoxic. Oral tiludronate administration was less effective and associated with nausea, vomiting, and an increase in serum creatinine levels. Tiludronate is not recommended for the treatment of tumor-associated hypercalcemia.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.

Author: VorotnjakMarta, BoosJoachim, Lanvers-KaminskyClaudia

Antitumor effects

Neuroblastoma is a type of childhood cancer that often metastasizes to the bone. Bisphosphonates are drugs that are used to treat bone metastasis. This study found that bisphosphonates were toxic to neuroblastoma cells, suggesting that they could be used as a treatment for neuroblastoma.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women.

Author: RavnP, RixM, AndreassenH, ClemmesenB, BidstrupM, GunnesM

Osteoporosis treatment
Spinal fracture

This study found a strong association between high bone turnover, low bone mass, and prevalence of spinal fracture in postmenopausal women. These results support the theory that high bone turnover is a risk factor for osteoporosis and spinal fracture.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

19.

A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.

Author: MurakamiH, TakahashiN, SasakiT, UdagawaN, TanakaS, NakamuraI, ZhangD, BarbierA, SudaT

Bone resorption inhibition

Tiludronate, a bisphosphonate, inhibited osteoclast-mediated bone resorption by disrupting the actin ring structure in osteoclasts.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review.

Author: Soleyman-JahiSaeed, YousefianAli, MaheronnaghshRadin, ShokranehFarhad, ZadeganShayan Abdollah, SoltaniAkbar, HosseiniSeyed Mostafa, VaccaroAlexander R, Rahimi-MovagharVafa

Spinal cord injury treatment

Spinal cord injury (SCI) can lead to osteoporosis. This review article discusses the prevention and treatment of osteoporosis in patients with SCI.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

21.

A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

Author: FraserW D, StampT C, CreekR A, SawyerJ P, PicotC

Reduced alkaline phosphatase
Reduced hydroxyproline
Reduced pain
Gastrointestinal symptoms

Oral tiludronate is an effective and well-tolerated treatment for Paget's disease. A 400 mg daily dose provides a good balance of efficacy and tolerability.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro.

Author: MönkkönenJ, SimiläJ, RogersM J

Bone resorption inhibition
Macrophage activation inhibition
Acute phase response
Fever

Liposome-mediated intracellular delivery of tiludronate, a metabolizable bisphosphonate, inhibited cytokine and nitric oxide secretion from activated macrophages, while ibandronate, an aminobisphosphonate, enhanced the production of cytokines.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.